Clinical Study of Leizumab Injection Combined with Cataract Phacoemulsification in Treatment of Cataract Complicated with Diabetes Macular Edema
Objective To analyze effect of Leizumab injection combined with phacoemulsification(PHACO+IOL)for cataract with diabetes macular edeMA(DME).Methods The paper chose 84 patients with cataracts and DME in our hospital from March 2022 to March 2023,and divided them into two groups randomly:control group(42 cases,treated with PHACO+IOL)and observation group(42 cases,with combination of ranibizumab injection and PHACO+IOL).Intraocular pressure,BCVA,and CMT levels before and after treatment were compared and analyzed between two groups.Results After treatment,both groups showed decrease in intraocular pressure and increase in BCVA levels.There was no significant difference in intraocular pressure between observation group and control group(P>0.05),while BCVA in observation group was significantly higher than control group(P<0.05).At 1,3,and 6 months after surgery,levels of CMT in both groups significantly decreased,observation group had lower levels than control group,(P<0.05).Incidence of complications in observation group(4.76%)was significantly lower than control group(21.43%),(P<0.05).Conclusion Combination of ranibizumab injection and cataract phacoemulsification can achieve ideal effect in clinical treatment of cataract patients with DME,can improve CMT,correct vision of patients effectively,which has high promotional feasibility.
Leizumab injectionPhacoemulsification treatment for cataractsCataractDiabetes macular edema
NETL
NSTL
万方数据
